Lista, Simone http://orcid.org/0000-0001-6804-7858
Santos-Lozano, Alejandro
Emanuele, Enzo http://orcid.org/0000-0003-3908-0290
Mercuri, Nicola B. http://orcid.org/0000-0001-6700-7491
Gabelle, Audrey
López-Ortiz, Susana
Martín-Hernández, Juan http://orcid.org/0000-0002-7840-1061
Maisto, Nunzia
Imbimbo, Camillo http://orcid.org/0000-0001-7747-806X
Caraci, Filippo
Imbimbo, Bruno P.
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Nisticò, Robert
Article History
Received: 6 July 2023
Revised: 4 December 2023
Accepted: 12 December 2023
First Online: 16 January 2024
Competing interests
: EE is the unique owner of 2E Science, a for-profit private scientific company. Neither EE nor 2E Science have any commercial interest or financial tie in relation with this article. BPI is an employee at Chiesi Farmaceutici. He is listed among the inventors of a number of Chiesi Farmaceutici’s patents of anti-Alzheimer drugs. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). SL, AS-L, NBM, AG, SL-O, JM-H, NM, CI, FC, and RN declare that they have no conflicts of interest.